ANZU SEC filings, in plain English
Everything Anzu Special Acquisition Corp I has filed with the SEC that we hold — 40 filings, newest first, 6 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: The filing reports the appointment of Robert Potashnick as Chief Accounting Officer and Vice President of Finance for Envoy Medical, Inc., effective August 24, 2026. The document details his compensation package: a base salary of $315,000 per year, an initial target bonus equal to 15% of his base salary contingent on performance goals, and an initial equity award of 250,000 stock options at an exercise price of $0.746 per share (the closing price of Class A Common Stock on the hire date). It also notes he is entitled to six months of severance compensation under certain termination conditions. Mr. Potashnick previously served as Interim-Chief Financial Officer on a contractor basis since June 2025. Why it matters: This filing discloses a change in principal financial and accounting officers, which is material for investors tracking management stability and governance. The specific terms of the employment agreement, including the equity grant size and exercise price, provide insight into the company's retention strategy and potential dilution. As the SPAC Anzu Special Acquisition Corp I is CLOSED, this filing pertains solely to the post-merger operating entity, Envoy Medical, Inc., rather than any SPAC-specific redemption or extension mechanics.
What changed: Envoy Medical, Inc. filed a preliminary proxy statement for a special stockholder meeting on October 12, 2026, to vote on a reverse stock split proposal with a ratio range of 1-for-5 to 1-for-25, authorized for implementation by December 31, 2026. The filing cites Nasdaq delisting risks due to failure to maintain a $1.00 minimum bid price, noting an initial notice received November 19, 2025, and a subsequent compliance deadline of November 16, 2026. Why it matters: Investors must evaluate the risk that the company will be delisted from Nasdaq if the reverse split is not approved or fails to sustain the share price above $1.00, which would severely limit capital access and liquidity. The filing confirms the SPAC merger entity (Envoy Medical) is actively managing listing compliance rather than liquidating, but highlights significant operational and financial distress.
What changed: Envoy Medical (NASDAQ: COCH) reported Q2 2026 results with $19.7M cash on hand, submitted the first of four FDA PMA modules for its Acclaim cochlear implant, and terminated its $15M ATM equity facility. The company also reported positive 12-month Stage 1 clinical trial data showing a 38.0 percentage point improvement in CNC word recognition scores. Why it matters: The PMA submission and positive clinical data mark key regulatory and clinical milestones toward potential commercialization, with the final module targeted for Q2 2027. The ATM termination and $19.7M cash position suggest the company believes its current capital is sufficient following a recent equity raise that brought in approximately $30M in gross proceeds.
What changed: Q2 2026 10-Q of Envoy Medical, Inc. (Nasdaq: COCH). Cash rose to $19,679 thousand at June 30, 2026 from $3,739 thousand at December 31, 2025 and total assets to $23,949 thousand from $8,558 thousand, funded by a February 2026 offering of Class A common stock, pre-funded warrants and Series A warrants; Class A shares outstanding rose to 77,194,595 from 28,934,960. Total liabilities were $20,255 thousand and stockholders' equity turned to $3,303 thousand from a $(12,158) thousand deficit. Why it matters: Revenue of $51 thousand a quarter is immaterial next to a $5.6 million operating loss; the balance sheet improvement is entirely from equity issuance that roughly tripled the share count in six months.
combination deadline, going-concern doubt, sponsor loans outstandingnothing moved · 3 with no prior record of ours
- Combination deadline
- 2028-12-31 · unchanged
- Going-concern doubt
- stated · unchanged
- Sponsor loans outstanding
- $10K · unchanged
The clause …“the Company agreed to extend the expiration date of the Term Loan Warrants to December 31, 2028. Prior to the extension, the Term Loan Warrants had expiration dates ranging from February 27, 2026 to June 26, 2027. In addition, Glen A.”…
The clause …“in consolidation. 2. Summary of Significant Accounting Policies Liquidity and Going Concern Since inception, the Company has historically incurred negative operating cash flows and losses from operations as the Company advances the”…
The clause …“additional advances of $ 2,500 under the February 2024 Term Loan. The outstanding balance on the February 2024 Term Loan, net of discount, was $ 10,369 at the time the debt was extinguished as discussed below. The February 2024”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Envoy Medical, Inc., successor to Anzu Special Acquisition Corp I, terminated its At The Market Offering Agreement dated January 17, 2025, effective June 24, 2026, reported under Item 1.02. A press release on the termination is attached as Exhibit 99.1 and is furnished rather than filed. Why it matters: An at-the-market facility is a standing route to sell shares into the market, so ending it removes both a source of continuing dilution and a source of ready funding. The filing gives no reason for the termination and names no replacement facility.
sponsor loans outstanding, combination deadline, going-concern doubtnothing moved · 3 with no prior record of ours
- Sponsor loans outstanding
- not previously extracted$10K
- Combination deadline
- 2028-12-31 · unchanged
- Going-concern doubt
- stated · unchanged
The clause …“additional advances of $ 2,500 under the February 2024 Term Loan. The outstanding balance on the February 2024 Term Loan, net of discount, was $ 10,369 at the time the debt was extinguished as discussed below. The February 2024”…
The clause …“the Company agreed to extend the expiration date of the Term Loan Warrants to December 31, 2028. Prior to the extension, the Term Loan Warrants had expiration dates ranging from February 27, 2026 to June 26, 2027. In addition, Glen A.”…
The clause …“per share data) 2. Summary of Significant Accounting Policies Liquidity and Going Concern Since inception, the Company has historically incurred negative operating cash flows and losses from operations as the Company advances the”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Envoy Medical, Inc., the successor to Anzu Special Acquisition Corp I, will hold its 2026 annual meeting in person at the offices of Fredrikson & Byron, 60 South Sixth Street, Minneapolis on May 12, 2026 at 3:00 p.m. local time, record date March 13, 2026. Six proposals include amendments to the 2023 Equity Incentive Plan and 2023 ESPP and, under Nasdaq Listing Rule 5635(d), approval of warrants to purchase Class A Common Stock and the underlying shares. Why it matters: Two consecutive going-concern opinions sit alongside a Nasdaq 20% Rule warrant vote and a plan amendment lifting the 2023 pool to 10,000,000 shares - about 11.5% of Class A outstanding, or 8.8% counting pre-funded warrants. Holders are being asked to fund a company the auditor twice declined to affirm can continue, and to do it through dilution. The Anzu trust was released at the de-SPAC, so there is no cash floor beneath the stock.
What changed vs 2025-10-17going concern APPEAREDgoing-concern doubt1 moved
- Going-concern doubt
- not statedstated
SpacBrain reads this as the substantial-doubt sentence is in this filing and not in the previous one.
The clause …“except that each such report contained an explanatory paragraph expressing substantial doubt about the Company’s ability to continue as a going concern. Furthermore, during each of the fiscal years ended December 31, 2025, and”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
- What changed vs 2025-03-31deadline 2025-12-31 → 2028-12-31
combination deadline, sponsor loans outstanding, going-concern doubt1 moved · 2 with no prior record of ours
- Combination deadline
- 2025-12-312028-12-31
- Sponsor loans outstanding
- not previously extracted$10K
- Going-concern doubt
- stated · unchanged
SpacBrain reads this as 1096 days later than the previous record.
The clause …“the Company agreed to extend the expiration date of the Term Loan Warrants to December 31, 2028. Prior to the extension, the Term Loan Warrants had expiration dates ranging from February 27, 2026 to June 26, 2027. In addition, Glen”…
The clause …“additional advances of $ 2,500 under the February 2024 Term Loan. The outstanding balance on the February 2024 Term Loan, net of discount, was $ 10,369 at the time the debt was extinguished as discussed below, and $ 9,489 as of”…
The clause …“stock. ● Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all. ●”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.